Updated geometry description for the LHCb Trigger Tracker

The XML based detector description for the Trigger Tracker (TT) station has been updated. A more realistic version has been implemented in which volumes for frames, readout cables, balconies, jackets, cooling plates and elements have been added in addition to a detailed description of the detector modules. In this note an overview of the updated description is presented

Provisions for oil and gas decommissioning costs: compliance with disclosure requirements by oil and gas companies listed in the UK

Due to their complications in terms of uncertainty and calculations provisions for oil and gas decommissioning costs are not easy to be understood and interpret by users of no accounting and finance background. Furthermore, due to their significant sizes, cash outflow effect and importance for decision making disclosing more detailed information seem to be ideal requirement to simplify these complications. This study raises, almost for the first time, queries about compliance, sufficiency, uniformity and fairness of oil and gas companies' disclosure practices with regard to provisions for decommissioning costs. In order to provide answers to the research quires, annual reports of 69 oil and gas companies listed in the UK were analysed and thirteen interviews with different professionals were conducted. Our results reveal that whilst there is sufficient standards to regulate accounting for provisions for decommissioning costs there seems to be lack of compliance with requirements of international accounting standards in terms of disclosing information on provisions for decommissioning costs. In many cases, and probably due to their sensitive nature, we found that oil and gas companies tend to disclose a minimum amount of information about provisions for decommissioning costs

New waterboatmen records for Western Canada (Hemiptera: Corixidae)

Trichocorixa verticalis (Fieber) is reported for the first time from the mainland of British Columbia and the subspecific assignment is discussed. Based on specimens in the Spencer Entomological Museum, one provincial record and one territorial record are added to the recent checklist of Canadian Hemiptera

Applicability and Utility of the Astromaterials X-Ray Computed Tomography Laboratory at Johnson Space Center

The Astromaterials Acquisition and Curation Office at NASAs Johnson Space Center is responsible for curating all of NASAs astromaterial sample collections (i.e. Apollo samples, Luna Samples, Antarctic Meteorites, Cosmic Dust Particles, Microparticle Impact Collection, Genesis solar wind atoms, Stardust comet Wild-2 particles, Stardust interstellar particles, and Hayabusa asteroid Itokawa particles) [1-3]. To assist in sample curation and distribution, JSC Curation has recently installed an X-ray computed tomography (XCT) scanner to visualize and characterize samples in 3D. [3] describes the instrumental set-up and the utility of XCT to astromaterials curation. Here we describe some of the current and future projects and illustrate the usefulness of XCT in studying astromaterials

The initial development of a jet caused by fluid, body and free surface interaction with a uniformly accelerated advancing or retreating plate. Part 1. The principal flow

The free surface and flow field structure generated by the uniform acceleration (with dimensionless acceleration σ) of a rigid plate, inclined at an angle α ∈ (0, π/2) to the exterior horizontal, as it advances (σ > 0) or retreats (σ < 0) from an initially stationary and horizontal strip of inviscid, incompressible fluid under gravity, are studied in the small-time limit via the method of matched asymptotic expansions. This work generalises the case of a uniformly accelerating plate advancing into a fluid as studied in Needham et al. (2008). Particular attention is paid to the innermost asymptotic regions encompassing the initial interaction between the plate and the free surface. We find that the structure of the solution to the governing initial boundary value problem is characterised in terms of the parameters α and μ (where μ = 1+σ tan α), with a bifurcation in structure as μ changes sign. This bifurcation in structure leads us to question the well-posedness and stability of the governing initial boundary value problem with respect to small perturbations in initial data in the innermost asymptotic regions, the discussion of which will be presented in the companion paper Gallagher et al. (2016) . In particular, when (α, μ) ∈ (0, π/2) × R+, the free surface close to the initial contact point remains monotone, and encompasses a swelling jet when (α, μ) ∈ (0, π/2)×[1,∞), or a collapsing jet when (α, μ) ∈ (0, π/2) × (0, 1). However, when (α, μ) ∈ (0, π/2) × R−, the collapsing jet develops a more complex structure, with the free surface close to the initial contact point now developing a finite number of local oscillations, with near resonance type behaviour occurring close to a countable set of critical plate angles α = α∗n ∈ (0, π/2) (n = 1, 2, . . .)

Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study

Objective Neuroinflammation is an important pathogenic mechanism in amyotrophic lateral sclerosis (ALS), with regulatory T cells (Tregs) mediating a slower rate of disease progression. Dimethyl fumarate enhances Treg levels and suppresses pro-inflammatory T cells. The present study assessed the safety and efficacy of dimethyl fumarate in ALS. Methods Phase-2, double-blind, placebo-controlled randomised clinical trial recruited participants from May 1, 2018 to September 25, 2019, across six Australian sites. Participants were randomised (2:1 ratio) to dimethyl fumarate (480 mg/day) or matching placebo, completing visits at screening, baseline, weeks 12, 24 and 36. The primary efficacy endpoint was a change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) at week 36. Secondary outcome measures included survival, neurophysiological index (NI), respiratory function, urinary neurotrophin-receptor p75 and quality of life. Results A total of 107 participants were randomised to dimethyl fumarate (n = 72) or placebo (n = 35). ALSFRS-R score was not significantly different at week 36 (−1.12 [−3.75 to 1.52, p = 0.41]). Dimethyl fumarate was associated with a reduced NI decline week 36 (differences in the least-squares mean: (0.84 [−0.51 to 2.22, p = 0.22]). There were no significant differences in other secondary outcome measures. Safety profiles were comparable between groups. Interpretation Dimethyl fumarate, in combination with riluzole, was safe and well-tolerated in ALS. There was no significant improvement in the primary endpoint. The trial provides class I evidence for safety and lack of efficacy of dimethyl fumarate in ALS